By Nick Paul Taylor
The U.K. has approved an oral suspension version of Bayer’s anticoagulant Xarelto to treat venous thromboembolism (VTE) in children. Bayer developed the formulation to eliminate the need for kids with VTE to have injections or regular monitoring.
read more
By Nick Paul Taylor
Laboratoires Théa has secured the European rights to the low-dose atropine eye drop NVK-002 from Nevakar in a deal worth up to $135 million. Nevakar is developing the candidate as a treatment for nearsightedness in children.
read more
By Nick Paul Taylor
Researchers have claimed “a major step forward” in the development of radio-labeled, microcapsule drug delivery systems. The microcapsules are designed to address shortcomings of existing delivery systems such as low drug loading capacities.
read more
By Beth Snyder Bulik,Fraiser Kansteiner
Syringe makers are scrambling to meet demand for so-called low dead space syringes as Pfizer and the U.S. look to squeeze out extra vaccine doses. Physicians and pharmacists discovered the potential extra dose after they began vaccinating patients, but initial enthusiasm has been dampened by the requirement of the now-scarce specialty needles to extract the last bit from each vial.
read more
Sponsored By: Medidata, a Dassault Systèmes company
8 parameters to optimize your “Path to Virtualization” across site- and patient-centric capabilities in this Sponsor Edition eBook.
Sponsored By: LabVantage Solutions
Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem.
Sponsored By: Acorn AI, a Medidata Company
Acorn AI has developed a flexible and scalable Commercial Data Model that provides pharmaceutical companies with the data-driven insights required to respond to the industry’s ever-changing landscape. Download the whitepaper to learn how Acorn AI’s intuitive data model enables launch success and more.
Sponsored By: Polpharma Biologics
Innovative cell lines and early process development are critical to generate a high producing cell lines alongside a USP strategy to meet high quality standards.
Sponsored by: Catalent
Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.
Sponsored by: Catalent
In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site.
.png)
